Kanada - anglų - Health Canada

bavarian nordic as - inactivated rabies virus (flury lep) - powder for solution - 2.5unit - inactivated rabies virus (flury lep) 2.5unit - vaccines

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

sanofi pasteur inc. - poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - poliovirus type 1 antigen (formaldehyde inactivated) 40 [d'ag'u] in 0.5 ml - ipol vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. (28) it is recommended that all infants (as young as 6 weeks of age), unimmunized children, and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis. (29) following the eradication of poliomyelitis caused by wild poliovirus from the western hemisphere (including north and south america) (30), an ipv-only schedule was recommended to eliminate vapp. (7) all children should receive four doses of ipv at ages 2, 4, 6 to 18 months, and 4 to 6 years. opv is no longer available in the us and is not recommended for routine immunization. (7) previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with opv are not contraindications to completing the primary series of immunization with ipol vaccine. children of all ages should have their immuni

Kenija - anglų - Pharmacy and Poisons Board

glaxosmithkline pharmaceuticals kenya ltd likoni road, p.o. box 78392, 00507, nairobi, kenya - inactivated rabies virus (strain flury lep) - powder and solvent for solution for injection - 2.5 iu - viral vaccines: rabiesvaccines

Europos Sąjunga - anglų - EMA (European Medicines Agency)

laboratorios syva, s.a.u. - inactivated bluetongue virus, serotype 1, strain alg2006/01 e1, inactivated bluetongue virus, serotype 4, strain btv-4/spa-1/2004, inactivated bluetongue virus, serotype 8, strain bel2006/01 - inactivated viral vaccines - cattle; sheep - for active immunisation of sheep to prevent viraemia and reduce clinical signs and lesions caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* and clinical signs and lesions caused by bluetongue virus serotype 4for active immunisation of cattle to prevent viraemia caused by bluetongue virus serotypes 1 and/or 8 and/or to reduce viraemia* caused by bluetongue virus serotype 4.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

laboratorios hipra, s.a. - porcine parvovirus, strain nadl-2 and erysipelothrix rhusiopathiae, strain r32e11 (inactivated) - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.for the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by erysipelothrix rhusiopathiae, serotype 1 and serotype 2.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus - cats - for active immunisation of cats from eight weeks of age against:feline calicivirosis to reduce clinical signs.feline viral rhinotracheitis to reduce clinical signs and viral excretion.feline panleucopenia to prevent leucopenia and to reduce clinical signs.feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.duration of immunity: one year after the primary vaccination for all components.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

Filipinai - anglų - FDA (Food And Drug Administration)

broadchem philippines biopharma corporation - live attenuated canine distemper virus (cdv) , canine adenovirus type 1 (cav-1) , canine adenovirus type 2 (cav-2) , canine parvovirus (cpv) , canine parainfluenza virus (cpiv) , inactivated leptospira interrogans var. icterohaemorrhagiae , leptospira interrogans var. grippotyphosa , leptospira interrogans var. sejroe , rabies virus (rv) vaccine (vet.) - freeze-dried powder for injection (sc) - formulation: each ml (dose) contains: live attenuated canine distemper virus (cdv)...... >10^2.7-4.5 eid50 canine adenovirus type 1 (cav-1). .................. >10^3.5-7.5 tcid 50 canine adenovirus type 2 (cav-2)................... >10^3.5-7.5 tcid50 canine parvovirus (cpv)............. >10^2.1-3.6 hau canine parainfluenza virus (cpiv)..................... >10^3-6 ccid 50 inactivated leptospira interrogans var. icterohaemorrhagiae....... >32 vnab50 leptospira interrogans var. grippotyphosa.......>32 vnab50 leptospira interrogans var. sejroe............... >32 vnab 50 rabies virus (rv)................ >2 iu eid - egg infectious dose tcid-tissue culture infectious dose ccid-cell culture infectious dose hau - haemagglutination unit iu - international unit

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

federal state budgetary scientific institution chumakov federal scientific center for research and development of immune-and-bio - specific antigen of rabies virus vnukovo-32 strain - lyophilisate for solution for i/m injection - 2.5iu/ml

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

federal state budgetary scientific institution "chumakov federal scientific center for research and development of immune-and-bi - specific antigen of rabies virus "vnukovo-32" strain - lyophilisate and solvent for solution for i/m injection - 2.5iu/ml